Roche To File NDA For T-DM1 This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche confirms mid-single digit sales growth for 2010 in first-quarter earnings call, as oncology and emerging markets sales provide a boost.
You may also be interested in...
ImmunoGen Gains Momentum On Success Of T-DM1, The Herceptin Conjugate In Development By Roche/Genentech
Buoyed by the affirmation of its conjugation technology brought by the imminent filing of T-DM1, ImmunoGen is focused on building an internal pipeline with future emphasis co-development deals, not just outlicensing.
ImmunoGen Gains Momentum On Success Of T-DM1, The Herceptin Conjugate In Development By Roche/Genentech
Buoyed by the affirmation of its conjugation technology brought by the imminent filing of T-DM1, ImmunoGen is focused on building an internal pipeline with future emphasis co-development deals, not just outlicensing.
Making Expanded Access Programs Work For - Not Against - Your Trial Drug
Providing an investigational drug outside of a controlled trial carries inherent development risks, but it can also be a win-win proposition for patients and sponsors when managed well, veterans of "expanded access" programs say